3.09
Maravai Lifesciences Holdings Inc stock is traded at $3.09, with a volume of 785.00K.
It is down -0.64% in the last 24 hours and down -13.20% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
See More
Previous Close:
$3.11
Open:
$3.08
24h Volume:
785.00K
Relative Volume:
0.59
Market Cap:
$452.32M
Revenue:
$185.74M
Net Income/Loss:
$-230.76M
P/E Ratio:
-3.411
EPS:
-0.9059
Net Cash Flow:
$-70.72M
1W Performance:
+1.98%
1M Performance:
-13.20%
6M Performance:
+9.57%
1Y Performance:
+30.38%
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MRVI
Maravai Lifesciences Holdings Inc
|
3.09 | 455.25M | 185.74M | -230.76M | -70.72M | -0.9059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Stop Loss: What are Maravai LifeSciences Holdings Incs earnings expectationsEarnings Performance Report & Long-Term Capital Growth Strategies - baoquankhu1.vn
Maravai LifeSciences stock faces ongoing volatility amid restructuring efforts and biotech sector pr - AD HOC NEWS
Published on: 2026-03-25 14:27:07 - baoquankhu1.vn
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (M - The National Law Review
Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences Holdings, Inc. (MRVI) reports Q4 loss, beats revenue estimates - MSN
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity - Stock Titan
Maravai (MRVI) General Counsel has 39,976 shares withheld for taxes - Stock Titan
Maravai LifeSciences (NASDAQ:MRVI) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-03-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation | NDAQ:MRVI | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Analysts - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out - ACCESS Newswire
Maravai LifeSciences Holdings Q1 2025 Earnings Preview - MSN
2026-03-08 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out | NDAQ:MRVI | Press Release - Stockhouse
How rising interest rates impact Maravai LifeSciences Holdings Inc. stockEntry Point & Precise Trade Entry Recommendations - Naître et grandir
How does Maravai LifeSciences Holdings Inc score in quality rankings2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn
Targets Report: What are Maravai LifeSciences Holdings Incs earnings expectations2025 Price Targets & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - MarketBeat
Royce & Associates LP Has $5.06 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
First Eagle Investment Management LLC Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
MRVI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Maravai Lifesciences Charts Early Turnaround in 2025 - TipRanks
Maravai LifeSciences (NASDAQ:MRVI) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Assessing a Potential 14% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpStill a Buy? - MarketBeat
Is Maravai LifeSciences Holdings Inc.’s ROE strong enoughMarket Growth Report & Fast Exit and Entry Trade Guides - mfd.ru
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts - Investing.com Nigeria
Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Maravai LifeSciences Q4 Earnings Call Highlights - MarketBeat
Maravai LifeSciences Holdings, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-02-26 - Seeking Alpha
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call H - GuruFocus
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts By Investing.com - Investing.com South Africa
Earnings call transcript: Maravai Lifesciences Q4 2025 beats EPS forecast, stock jumps 4.5% - Investing.com Canada
MRVI: 2025 saw revenue beat, margin recovery, and strong 2026 growth and profitability guidance - TradingView
Maravai LifeSciences Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Maravai LifeSciences (NASDAQ:MRVI) Issues Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):